Filter by
Documents (141)
RSSShowing results 60 to 80
Approach to consulting academic stakeholders
Discussion on stakeholder priorities to advise ACT EU Steering Group
Report from CTR Collaborate stakeholder meeting held on 11 September
MSP AG report on the most frequently reported and major issues
Report to monitor the European clinical trials environment (1-30 September 2024)
Member States participating in ACT EU pilots on consolidated advice
Agenda MSP Advisory Group meeting 27 September 2024
Meeting highlights - MSP Advisory Group 4 July 2024
Report to monitor the European clinical trials environment (1-31 August 2024)
Report to monitor the European clinical trials environment (1-31 July 2024)
Report to monitor the European clinical trials environment (1-30 June 2024)
Challenges and possible options when designing a Platform Trial - F. Houyez (EURORDIS)
Challenges and possible options when designing a Platform Trial - F. Houyez (EURORDIS)
Challenges in performing mult-country Investigator Initiated Trials in EU - M. Zuidgeest (UMC Utrecht)
Challenges in performing mult-country Investigator Initiated Trials in EU - M. Zuidgeest (UMC Utrecht)
CTA review process and CTR implementation - L. Leyens (EFPIA)
CTA review process and CTR implementation - L. Leyens (EFPIA)
Enabling CTIS Public Data Use - F. Sweeney (CDDF)
Enabling CTIS Public Data Use - F. Sweeney (CDDF)
Enhancing and harmonizing Regulatory process for clinical trials- M. Heath (Vaccines Europe)
Enhancing and harmonizing Regulatory process for clinical trials- M. Heath (Vaccines Europe)
Innovative Study Designs in Paediatrics - D. Bonifazi (TEDDY)
Innovative Study Designs in Paediatrics - D. Bonifazi (TEDDY)
Limited Scientific advice for academic developers - D. Coppens (KWF)
Limited Scientific advice for academic developers - D. Coppens (KWF)
Low-intervention clinical trials - S. Kromar (EORTC)
Low-intervention clinical trials - S. Kromar (EORTC)
Paediatric patients involvement in the drug development - B. Nafria (eYPAGnet)
Paediatric patients involvement in the drug development - B. Nafria (eYPAGnet)
